Table 3 Changes in gastroesophageal reflux disease symptom scores from the baseline during on-demand treatment.

From: Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial

 

Heartburn

Regurgitation

 

Tegoprazan

50 mg

(n = 36)

Esomeprazole 20 mg

(n = 33)

p-value*

Tegoprazan

50 mg

(n = 36)

Esomeprazole

20 mg

(n = 33)

p-value*

Frequency score†, mean (SD)

Baseline

0.56 (0.69)

0.67 (0.89)

 

0.31 (0.52)

0.48 (0.97)

 

Week 8

1.06 (1.07)

0.94 (1.03)

 

0.64 (0.93)

0.73 (1.26)

 

△(8 − 0)

weeks

0.50 (1.32)

0.27 (1.31)

0.4715

0.33 (1.01)

0.24 (1.28)

0.7624

Week 4

1.11 (1.06)

1.00 (0.79)

 

0.75 (1.08)

0.58 (0.90)

 

△(4 − 0)

weeks

0.56 (1.16)

0.33 (1.22)

0.6989

0.44 (1.11)

0.09 (1.33)

0.4321

Severity score††, mean (SD)

Baseline

0.50 (0.61)

0.64 (0.74)

 

0.33 (0.59)

0.42 (0.79)

 

Week 8

1.00 (1.04)

0.91 (0.91)

 

0.67 (1.01)

0.55 (0.90)

 

△(8 − 0)

weeks

0.50 (1.23)

0.27 (1.21)

0.3331

0.33 (1.12)

0.12 (1.14)

0.3793

Week 4

1.03 (0.97)

1.06 (0.90)

 

0.69 (0.95)

0.61 (0.83)

 

△(4 − 0)

weeks

0.53 (1.06)

0.42 (1.23)

0.6448

0.36 (0.99)

0.18 (1.16)

0.5927

  1. SD standard deviation.
  2. *Mann–Whitney U test.
  3. †Frequency (0 = None, 1 = symptom for ≥ 1 and < 2 days per week, 2 = symptom for ≥ 2 and < 3 days per week, 3 = symptom for ≥ 3 and < 5 days per week, 4 = symptom for ≥ 5 days per week).
  4. ††Severity (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe).
Back to article page